Brind.

ImmunityBio presented Phase 3 clinical trial data, leading UBS to upgrade its rating from Neutral to Buy.

1 report, 1 independent Updated Jun 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

ImmunityBio UBS

Keep exploring

The entities involved

ImmunityBio
biotech company

Nothing else this week.
UBS
Swiss multinational investment bank and financial services company
- The Trump administration threatens tariffs on Switzerland, leading Switzerland to seek a new trade agreement with the US.Mon 00:13
- Following the acquisition of Credit Suisse, the Swiss parliament proposed new banking regulations for UBS.Sun 10:25

Coverage

Newest first; wire copies grouped

Jun 17benzinga.com